PDCD1 and non-small cell lung carcinoma: In the 2010s, immunotherapy, especially treatment with pembrolizumab (a monoclonal antibody of programmed cell death protein 1 [PD‐1] antibody), altered the treatment landscape for NSCLC patients without driver mutations.6, 7